Literature DB >> 16772527

Phosphorylation of phospholamban at threonine-17 reduces cardiac adrenergic contractile responsiveness in chronic pressure overload-induced hypertrophy.

Geoffrey D Mills1, Hajime Kubo, David M Harris, Remus M Berretta, Valentino Piacentino, Steven R Houser.   

Abstract

Physiological hemodynamic stress, such as aerobic exercise, is intermittent and requires an increase in Ca2+ -dependent contractility through sympathetic nervous system activation. Pathological hemodynamic stress, such as hypertension, is persistent and requires sustained increases in cardiac function. Over time, this causes left ventricular hypertrophy (LVH)-reduced responsiveness to sympathetic stimulation. In this study, we examined the hypothesis that blunted in vivo adrenergic contractile responsiveness in pressure overload (PO)-induced cardiac hypertrophy is caused by abnormalities in the abundance and/or basal phosphorylation state of Ca2+ regulatory proteins. PO, induced by aortic constriction, caused concentric LVH or dilated LVH. Only animals with dilation exhibited a decrease in baseline left ventricle function [fractional area change (FAC); measured with echocardiography]. All PO animals had a reduced contractile response to adrenergic agonists (increase in FAC with 40 microg.kg(-1).min(-1) dobutamine, control 0.30 +/- 0.04, n = 5 vs. banded 0.10 +/- 0.03, n = 10; P < 0.01). PO animals had reduced phospholamban (PLB) protein abundance (P = 0.07, not significant) and increased PLB phosphorylation at the calmodulin-dependent kinase II (CaMKII)-specific site (PLB-Thr17, P < 0.05) but not at the protein kinase A-specific site (PLB-Ser16). PLB-Thr17 phosphorylation was inversely correlated with dobutamine-induced increases in contractility in PO animals (r2 = 0.81, P < 0.05). Continuous induction of Ca2+ transients in isolated ventricular myocytes for 24 h increased phosphorylation at PLB-Thr17 and diminished inotropic responsiveness and PLB-Ser16 phosphorylation after exposure to isoproterenol (P < 0.05). These data show that reduced adrenergic responsiveness in feline PO hypertrophy and failure involves increases in basal PLB-Thr17 phosphorylation, suggesting that activation of CaMKII in PO hypertrophy contributes to defective adrenergic reserve in compensated LVH and early heart failure.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16772527     DOI: 10.1152/ajpheart.01353.2005

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  10 in total

1.  Phospholamban phosphorylation, mutation, and structural dynamics: a biophysical approach to understanding and treating cardiomyopathy.

Authors:  Naa-Adjeley D Ablorh; David D Thomas
Journal:  Biophys Rev       Date:  2015-01-21

2.  Role of STIM1 (Stromal Interaction Molecule 1) in Hypertrophy-Related Contractile Dysfunction.

Authors:  Constantine D Troupes; Markus Wallner; Giulia Borghetti; Chen Zhang; Sadia Mohsin; Dirk von Lewinski; Remus M Berretta; Hajime Kubo; Xiongwen Chen; Jonathan Soboloff; Steven Houser
Journal:  Circ Res       Date:  2017-06-07       Impact factor: 17.367

3.  Imatinib activates pathological hypertrophy by altering myocyte calcium regulation.

Authors:  Larry A Barr; Catherine A Makarewich; Remus M Berretta; Hui Gao; Constantine D Troupes; Felix Woitek; Fabio Recchia; Hajime Kubo; Thomas Force; Steven R Houser
Journal:  Clin Transl Sci       Date:  2014-06-16       Impact factor: 4.689

4.  Impaired contractile function and calcium handling in hearts of cardiac-specific calcineurin b1-deficient mice.

Authors:  Paul J Schaeffer; Jaime Desantiago; John Yang; Thomas P Flagg; Attila Kovacs; Carla J Weinheimer; Michael Courtois; Teresa C Leone; Colin G Nichols; Donald M Bers; Daniel P Kelly
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-08-21       Impact factor: 4.733

5.  A human phospholamban promoter polymorphism in dilated cardiomyopathy alters transcriptional regulation by glucocorticoids.

Authors:  Kobra Haghighi; Guoli Chen; Yoji Sato; Guo-Chang Fan; Suiwen He; Fotis Kolokathis; Luke Pater; Ioannis Paraskevaidis; W Keith Jones; Gerald W Dorn; Dimitrios Th Kremastinos; Evangelia G Kranias
Journal:  Hum Mutat       Date:  2008-05       Impact factor: 4.878

6.  Pathological hypertrophy and cardiac dysfunction are linked to aberrant endogenous unsaturated fatty acid metabolism.

Authors:  Loreta Casquel De Tomasi; Dijon Henrique Salomé Campos; Paula Grippa Sant'Ana; Katashi Okoshi; Carlos Roberto Padovani; Gilson Masahiro Murata; Son Nguyen; Stephen C Kolwicz; Antonio Carlos Cicogna
Journal:  PLoS One       Date:  2018-03-01       Impact factor: 3.240

7.  IRAG1 Deficient Mice Develop PKG1β Dependent Pulmonary Hypertension.

Authors:  Siladitta Biswas; Baktybek Kojonazarov; Stefan Hadzic; Michael Majer; Ganimete Bajraktari; Tatyana Novoyatleva; Hossein Ardeschir Ghofrani; Friedrich Grimminger; Werner Seeger; Norbert Weissmann; Jens Schlossmann; Ralph Theo Schermuly
Journal:  Cells       Date:  2020-10-13       Impact factor: 6.600

Review 8.  SERCA2a gene therapy in heart failure: an anti-arrhythmic positive inotrope.

Authors:  Markus B Sikkel; Carl Hayward; Kenneth T MacLeod; Sian E Harding; Alexander R Lyon
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

9.  Interaction of the Joining Region in Junctophilin-2 With the L-Type Ca2+ Channel Is Pivotal for Cardiac Dyad Assembly and Intracellular Ca2+ Dynamics.

Authors:  Polina Gross; Jaslyn Johnson; Carlos M Romero; Deborah M Eaton; Claire Poulet; Jose Sanchez-Alonso; Carla Lucarelli; Jean Ross; Andrew A Gibb; Joanne F Garbincius; Jonathan Lambert; Erdem Varol; Yijun Yang; Markus Wallner; Eric A Feldsott; Hajime Kubo; Remus M Berretta; Daohai Yu; Victor Rizzo; John Elrod; Abdelkarim Sabri; Julia Gorelik; Xiongwen Chen; Steven R Houser
Journal:  Circ Res       Date:  2020-10-23       Impact factor: 17.367

10.  Enhanced Ca²+ influx through cardiac L-type Ca²+ channels maintains the systolic Ca²+ transient in early cardiac atrophy induced by mechanical unloading.

Authors:  A P Schwoerer; S Neef; I Broichhausen; J Jacubeit; M Tiburcy; M Wagner; D Biermann; M Didié; C Vettel; L S Maier; W H Zimmermann; L Carrier; T Eschenhagen; T Volk; A El-Armouche; H Ehmke
Journal:  Pflugers Arch       Date:  2013-07-11       Impact factor: 3.657

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.